Title:
CONJUGATES, COMPOSITIONS AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO/2023/131219
Kind Code:
A1
Abstract:
Described herein are methods and compositions for the targeted delivery of therapeutic agents. Provided herein are compounds and conjugates of the formulas described herein, including antibody-linker conjugates, comprising comprising one or more moieties derived from therapeutic agents (a topoisomerase inhibitor or a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor), and wherein the conjugate further comprises a polypeptide, such as an antibody. The present disclosure also provides compositions comprising such conjugates and uses and methods for treating diseases and disorders, such as cancer, using these conjugates.
More Like This:
Inventors:
SHI LEI (CN)
JACKSON DAVID Y (US)
WONG OI KWAN (US)
FEI QI (CN)
JACKSON DAVID Y (US)
WONG OI KWAN (US)
FEI QI (CN)
Application Number:
PCT/CN2023/070618
Publication Date:
July 13, 2023
Filing Date:
January 05, 2023
Export Citation:
Assignee:
VIRTUOSO BINCO INC (US)
SHI LEI (CN)
SHI LEI (CN)
International Classes:
A61K47/68; A61P35/00; C07K16/28
Domestic Patent References:
| WO2020219287A1 | 2020-10-29 | |||
| WO2015155998A1 | 2015-10-15 | |||
| WO2015095755A1 | 2015-06-25 | |||
| WO2006034488A2 | 2006-03-30 |
Foreign References:
| US4496542A | 1985-01-29 | |||
| US7709226B2 | 2010-05-04 |
Other References:
NAKADA TAKASHI ET AL: "Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 26, no. 6, 8 February 2016 (2016-02-08), pages 1542 - 1545, XP029436554, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2016.02.020
T. M. CARDILLO ET AL: "Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys", CLINICAL CANCER RESEARCH, vol. 17, no. 10, 3 March 2011 (2011-03-03), US, pages 3157 - 3169, XP055398728, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2939
PIETERSZ G A ET AL: "LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival", TRANSPLANT IMMUNOLOGY, ELSEVIER, NL, vol. 9, no. 1, 1 October 2001 (2001-10-01), pages 7 - 11, XP027388165, ISSN: 0966-3274, [retrieved on 20011001]
CHRISTINA M. ANNUNZIATA ET AL: "Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors", INVESTIGATIONAL NEW DRUGS, vol. 31, no. 1, 1 February 2013 (2013-02-01), New York, pages 77 - 84, XP055565551, ISSN: 0167-6997, DOI: 10.1007/s10637-012-9801-2
SPATOLA, CHEM. BIOCHEM. AMINO ACIDS AND PROTEINS, vol. 7, 1983, pages 267 - 357
TRAMONTANO A ET AL., J. MOL. BIOL., vol. 215, no. 1, 1990, pages 175 - 970
BERGE S.M. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1997, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
KABAT ET AL., ANN. NY ACAD. SCI., vol. 190, January 1997 (1997-01-01), pages 382 - 391
MARKS, J.D. ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
AL-LAZIKANI ET AL., J. MOL. BIOL., vol. 273, 1997, pages 927 - 948
HOOGENBOOM, H.R.WINTER, G., J. MOL. BIOL., vol. 227, 1992, pages 381 - 388
LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LEFRANC, M.-P. ET AL., NUCLEIC ACIDS RES., vol. 27, 1999, pages 209 - 212
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
MARTIN, A.: "Antibody Engineering", vol. 31, 2001, SPRINGER- VERLAG, article "Protein Sequence and Structure Analysis of Antibody Variable Domains", pages: 422 - 439
VAN DIJK, M.A.VAN DE WINKEL, J.G., CURR. OPIN. CHEM. BIOL., vol. 5, 2001, pages 368 - 374
JAKOBOVITS, A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 2555
JAKOBOVITS, A. ET AL., NATURE, vol. 362, 1993, pages 255 - 258
BRUGGEMANN, M. ET AL., YEAR IMMUNOL, vol. 7, 1993, pages 33 - 40
COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, pages: 77
BOERNER, P. ET AL., J. IMMUNOL., vol. 147, 1991, pages 86 - 95
JUNUTULA ET AL., J. IMMUNOL. METH., vol. 332, 2008, pages 41 - 52
JUNUTULA ET AL., NATURE BIOTECHNOL., vol. 26, 2008, pages 925 - 32
HOFER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, 2008, pages 12451 - 56
HOFER ET AL., BIOCHEMISTRY, vol. 48, no. 50, 2009, pages 12047 - 57
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING COMPANY
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
"Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS
T. M. CARDILLO ET AL: "Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys", CLINICAL CANCER RESEARCH, vol. 17, no. 10, 3 March 2011 (2011-03-03), US, pages 3157 - 3169, XP055398728, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2939
PIETERSZ G A ET AL: "LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival", TRANSPLANT IMMUNOLOGY, ELSEVIER, NL, vol. 9, no. 1, 1 October 2001 (2001-10-01), pages 7 - 11, XP027388165, ISSN: 0966-3274, [retrieved on 20011001]
CHRISTINA M. ANNUNZIATA ET AL: "Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors", INVESTIGATIONAL NEW DRUGS, vol. 31, no. 1, 1 February 2013 (2013-02-01), New York, pages 77 - 84, XP055565551, ISSN: 0167-6997, DOI: 10.1007/s10637-012-9801-2
SPATOLA, CHEM. BIOCHEM. AMINO ACIDS AND PROTEINS, vol. 7, 1983, pages 267 - 357
TRAMONTANO A ET AL., J. MOL. BIOL., vol. 215, no. 1, 1990, pages 175 - 970
BERGE S.M. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1997, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
KABAT ET AL., ANN. NY ACAD. SCI., vol. 190, January 1997 (1997-01-01), pages 382 - 391
MARKS, J.D. ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
AL-LAZIKANI ET AL., J. MOL. BIOL., vol. 273, 1997, pages 927 - 948
HOOGENBOOM, H.R.WINTER, G., J. MOL. BIOL., vol. 227, 1992, pages 381 - 388
LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LEFRANC, M.-P. ET AL., NUCLEIC ACIDS RES., vol. 27, 1999, pages 209 - 212
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
MARTIN, A.: "Antibody Engineering", vol. 31, 2001, SPRINGER- VERLAG, article "Protein Sequence and Structure Analysis of Antibody Variable Domains", pages: 422 - 439
VAN DIJK, M.A.VAN DE WINKEL, J.G., CURR. OPIN. CHEM. BIOL., vol. 5, 2001, pages 368 - 374
JAKOBOVITS, A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551 - 2555
JAKOBOVITS, A. ET AL., NATURE, vol. 362, 1993, pages 255 - 258
BRUGGEMANN, M. ET AL., YEAR IMMUNOL, vol. 7, 1993, pages 33 - 40
COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, pages: 77
BOERNER, P. ET AL., J. IMMUNOL., vol. 147, 1991, pages 86 - 95
JUNUTULA ET AL., J. IMMUNOL. METH., vol. 332, 2008, pages 41 - 52
JUNUTULA ET AL., NATURE BIOTECHNOL., vol. 26, 2008, pages 925 - 32
HOFER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, 2008, pages 12451 - 56
HOFER ET AL., BIOCHEMISTRY, vol. 48, no. 50, 2009, pages 12047 - 57
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING COMPANY
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
"Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS
Attorney, Agent or Firm:
AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF: